Although NAMPT inhibitors have entered clinical trials as a single agent (FK866/APO866 and GMX1777/GMX1778), these failed to progress to phase 2 due to on-target dose-limiting toxicity (mainly thrombocytopenia) and lack of clinical efficacy39. This evidence concerns the gene NAMPT and Thrombocytopenia.